Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors
NCT05039801Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2021
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of IPN60090 in solid tumor, endometrial carcinoma, head and neck squamous cell carcinoma (HNSCC) and 4 more (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of adverse events at 90 days. Started Sep 2021; status: recruiting.
02
Drugs
IPN60090
03
Conditions
solid tumorendometrial carcinomahead and neck squamous cell carcinoma (HNSCC)melanomaovarian cancer
Beyond the preview
Go deeper on NCT05039801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05039801.